Large cap pharma defensive AI winner, says RBC as it backs Lilly & AbbVie

RBC analysts say U.S. large cap pharma offers defensive exposure and earnings upside as artificial intelligence reshapes drug development.
Mirage News

FDA Fully Approves Pfizer's BRAFTOVI for Metastatic CRC

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in ...
Business Wire

U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in combination ...

Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee

As Chair of the Scientific Advisory Committee, Dr. Lewis-Hall will provide leadership in scientific, clinical, and regulatory governance across Helus' portfolio, advising on discovery opportunities, ...